Closing Loopholes for Orphan Drugs Act
Summary
Closing Loopholes for Orphan Drugs Act This bill revises the 340B Drug Pricing Program, which currently requires drug manufacturers to discount orphan drugs (i.e., drugs for rare conditions) for certain entities covered by the program. The bill discounts orphan drugs that are not being used to treat rare conditions for all entities covered by the program.
Bill status
in committee
1 of 4 stages cleared
Introduction
Feb 2021
Committee Review
Floor Vote
President
Introduced Feb 4, 2021
Last action Feb 5, 2021
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
3
Key actions
0
Committee
2
Feb 5, 2021
Committee
Referred to the Subcommittee on Health.
lower
Feb 4, 2021
Committee
Referred to the House Committee on Energy and Commerce.
lower
Feb 4, 2021
Introduced
Introduced in House
lower
1 primary · 1 co-sponsor
Sponsors
Ask Maddy
·
AI policy assistant
Ask Maddy about HR 853
Scope: US
Hi! I can help you understand HR 853. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline